Bevacizumab nasal spray: Noninvasive treatment of epistaxis in patients with rendu-osler disease

Laryngoscope

Volumn 122, Issue 5, 2012, Pages 953-955

  Guldmann, Romain ^a   Dupret, Agnes ^a   Nivoix, Yasmine ^a   Schultz, Philippe ^a   Debry, Christian ^a  

^a HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

bevacizumab; epistaxis; hereditary hemorrhagic telangiectasia; Rendu Osler; treatment

Indexed keywords

BEVACIZUMAB;

ADULT; AGEUSIA; ANOSMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EPISTAXIS; EPISTAXIS SEVERITY SCORE; FEMALE; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RENDU OSLER WEBER DISEASE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INTRANASAL; AEROSOLS; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DOSE-RESPONSE RELATIONSHIP, DRUG; EPISTAXIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NASAL SPRAYS; PROSPECTIVE STUDIES; QUALITY OF LIFE; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84859911496     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.23230     Document Type: Article

References (14)

1. Westermann CJ, Rosina AF, De Vries V, de Coteau PA,. The prevalence and manifestations of hereditary hemorrhagic telangiectasia in the Afro-Caribbean population of the Netherlands Antilles: a family screening. Am J Med Genet A 2003; 116A: 324-328. (Pubitemid 37063583)
2. Guttmacher AE, Marchuk DA, White RI Jr,. Hereditary hemorrhagic telangiectasia. N Engl J Med 1995; 333: 918-924.
3. Geisthoff UW, Schneider G, Fischinger J, Plinkert PK, Hereditary hemorrhagic telangiectasia (Osler's disease),. An interdisciplinary challenge [in German]. HNO 2002; 50: 114-128.
4. Sadick H, Naim R, Sadick M, Hormann K, Riedel F, Plasma level and tissue expression of angiogenic factors in patients with hereditary hemorrhagic telangiectasia. Int J Mol Med 2005; 15: 591-596.
5. Flieger D, Hainke S, Fischbach W,. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol 2006; 85: 631-632. (Pubitemid 44283088)
6. Koukourakis GV,. Has bevacizumab (Avastin) given extra therapeutic gain in metastatic colorectal cancer and malignant brain gliomas? Systematic review answering this question. Recent Pat Inflamm Allergy Drug Discov 2012; 6: 70-77.
7. Fong DS, Custis P, Hownes J, Hsu JW,. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study. Ophthalmology 2010; 117: 298-302.
8. Karnezis TT, Davidson TM,. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 2011; 121: 636-638.
9. Chen S, Karnezis T, Davidson TM,. Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia- associated epistaxis. Laryngoscope 2011; 121: 644-646.
10. Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000; 91: 66-67. (Pubitemid 30127562)
11. Hoag JH, Terry P, Mitchell S, Reh D, Merlo CA,. An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope 2010; 120: 838-843.
12. Lund VJ, Howard DJ,. Closure of the nasal cavities in the treatment of refractory hereditary haemorrhagic telangiectasia. J Laryngol Otol 1997; 111: 30-33. (Pubitemid 27089218)
13. Simonds J, Miller F, Mandel J, Davidson TM,. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 2009; 119: 988-992.
14. Samson G, Garcia de la Calera A, Dupuis-Girod S, et al. Ex vivo study of bevacizumab transport through porcine nasal mucosa. Eur J Pharm Biopharm. Available online November 18, 2011, in press.